Maintenance avelumab in metastatic urothelial cancer patients
2021
The treatment outcomes of patients with metastatic urothelial carcinoma remain poor. Despite the relatively high response rate to platinum-based chemotherapy, the median overall survival doesn't exceed 14 months. Immunotherapy with anti-PD-1/anti-PD-L1 antibodies in the second-line treatment shows significant activity but nearly 50% of patients are not eligible for such treatment because of poor performance status. Therefore, there is a need for new treatment strategies. In the phase III JAVELIN Bladder 100 clinical trial, the maintenance treatment with avelumab in patients who achieved disease control with platinum-based first-line chemotherapy resulted in prolongation of overall survival and progression-free survival with good safety profile.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI